Are you looking to stay current with all of the latest Pulmonology news articles and research? Look no further! MDLinx Pulmonology medical editors extensively research respiratory medical journals to find the most beneficial Pulmonology clinical literature. Topics range from: Pediatric Pulmonology, Sleep Disorders, Asthma, COPD, Cystic Fibrosis and much more. In a matter of minutes, Pulmonologists and their staff can stay up to date with the most current published information.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We also feature clinical pearls from our Internal Medicine Physician Review. You can also get the latest updates on salary information, search available Pulmonology jobs, view upcoming Pulmonology and CME conferences and earn some extra cash by participating in Market Research opportunities.
Not yet an MDLinx.com Member??? Sign up now to gain access to MDLinx exclusive content, email alerts that keep you current on the latest medical news, research, and clinical articles on the topics of your choice, special communications and offers from MDLinx and our sponsors. Plus, you can now post your CV to the MDLinx Career Center to be viewed top medical recruiters who will help you find your next dream job.
Your Unread Messages in Pulmonology
See All >> Messages include industry-sponsored communications and special communications from MDLinx
Smartest Doc Challenge
MDLinx
Lung Cancer Clinical Pearls
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
D Scott Cunningham MD, PhD
Site Editor, MDLinx
ASA reduces risk of ACS in hospitalized pneumonia patients
1 Benefits of combining inspiratory muscle with ‘whole muscle’ training in children with cystic fibrosis: a randomised controlled trial British Journal of Sports Medicine, May 21, 2013 Evidence Based Medicine
2 Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR Journal of Medical Genetics, May 21, 2013 Review Article
3 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial European Respiratory Journal , May 20, 2013 Clinical Article
4 Aortopulmonary collateral flow in cystic fibrosis assessed with phase-contrast MRI Pediatric Radiology, May 17, 2013 Clinical Article
5 Mitochondrial OXPHOS function is unaffected by chronic azithromycin treatment Journal of Cystic Fibrosis, May 16, 2013 Clinical Article
6 Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan - A Parallel, Randomized Trial Annals of Internal Medicine, May 15, 2013 Clinical Article
7 Phenotyping adults with non-cystic fibrosis bronchiectasis: A prospective observational cohort study Respiratory Medicine, May 15, 2013 Clinical Article
8 Cystic fibrosis and fertility Current Opinion in Obstetrics and Gynecology, May 15, 2013 Clinical Article
9 Stunting is an independent predictor of mortality in patients with cystic fibrosis Clinical Nutrition, May 15, 2013 Review Article
10 Skin pretreatment with microneedles prior to pilocarpine iontophoresis increases sweat production Clinical Physiology and Functional Imaging, May 15, 2013 Clinical Article
11 Non-invasive ventilation for cystic fibrosis Cochrane Reviews, May 14, 2013 Evidence Based Medicine Clinical Article
12 Cystic fibrosis in the era of genomic medicine Current Opinion in Pediatrics, May 14, 2013 Review Article
13 Comparison of Lung Clearance Index Measured During Helium Washin and Washout in Children With Cystic Fibrosis Pediatric Pulmonology, May 14, 2013 Clinical Article
14 Diagnosis and Management of Concomitant Cystic Fibrosis in Patients With Chronic Obstructive Pulmonary Disease Clinical Pulmonary Medicine, May 14, 2013
15 Angiotensin-Converting Enzyme (ACE) Gene Polymorphisms are Associated with Idiopathic Pulmonary Fibrosis Lung, May 13, 2013 Clinical Article
16 Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition Thorax, May 10, 2013 Clinical Article
17 Genetic background of idiopathic pulmonary fibrosis Expert Review of Molecular Diagnostics, May 10, 2013 Review Article
18 Vitamin K supplementation for cystic fibrosis Cochrane Reviews, May 9, 2013 Evidence Based Medicine Clinical Article
19 Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis Respiratory Medicine, May 9, 2013 Clinical Article
20 Nebuliser systems for drug delivery in cystic fibrosis Cochrane Reviews, May 9, 2013 Evidence Based Medicine Clinical Article
Using a murine mouse model of pneumonia, prolonged simvastatin therapy has a measureable effect on Streptococcus pneumoniae infection, but no effect on mortality. Mice were treated with simvastatin (1 mg/kg/d [low dose] or 10 mg/kg/d [high dose]) for 4 weeks, then infected with S. pneumoniae intrathecally. Mice treated with the high-dose regimen had less lung consolidation, decreased macrophage and neutrophil infiltration, decreased MCP-1, KC, and ICAM-1 production, and decreased bacterial titers in the blood 36 and 42 h post-infection. Despite these favorable physiologic effects, there was no effect on mortality compared to control mice treated with ampicillin 48 h post-infection.
Read the article summaryAs published in the European Journal of Internal Medicine, there were no mortalities in patients with community-acquired pneumonia (CAP) and low levels of D-dimer (< 500 ug/l). Of 147 patients in the study, D-dimer levels were elevated in those with severe CAP (2166 vs. 1630 ug/l), day 30-clinical failure (2228 vs. 1594 ug/l), early failure (2499 vs. 1669 ug/l), and non-survivors (3025 vs. 1680 ug/l). Importantly, D-dimer levels were not shown to be associated with clinical outcome based on multivariate analysis.
Read the article summaryAs published in the Journal of Infection, 114 of 981 (11.6%) of patients with pneumococcal pneumonia were bacteremic. Risk factors for bacteremia included immunosuppressants, age < 65 years, and diabetes mellitus. Patients with pneumococcal pneumonia and bacteria were at increased risk for mortality (28.6% vs. 8.5%). The combination of bacteremia, cerebrovascular disease, and septic shock had a strong association with mortality in patients with pneumococcal pneumonia.
Read the article summaryIndexed Journals in Pulmonology: Chest, Thorax, American Journal of Respiratory and Critical Care Medicine more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close